Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Circulation
    April 2024
  1. SANDHU AT, Calma J, Skye M, Kalwani NM, et al
    Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624.
    >> Share

  2. HERNANDEZ AF, Udell JA, Jones WS, Anker SD, et al
    Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
    Circulation. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217.
    >> Share

  3. BREATHETT K, Lewsey S, Brownell NK, Enright K, et al
    Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Apr 3. doi: 10.1161/CIR.0000000000001231.
    >> Share


  4. Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2024;149:e1066.
    >> Share

  5. GOKULNATH P, Spanos M, Lehmann HI, Sheng Q, et al
    Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach.
    Circulation. 2024;149:1147-1149.
    >> Share

  6. KAPELIOS CJ, Lund LH
    Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure.
    Circulation. 2024;149:1062-1064.
    >> Share

    March 2024
  7. BERG-HANSEN K, Gopalasingam N, Christensen KH, Ladefoged B, et al
    Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
    Circulation. 2024 Mar 27. doi: 10.1161/CIRCULATIONAHA.123.067971.
    >> Share

  8. JESSUP M
    A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress.
    Circulation. 2024;149:899-901.
    >> Share

  9. CLELAND JGF
    Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure.
    Circulation. 2024;149:839-842.
    >> Share

  10. VELIKANOVA D, Poyhonen P, Lehtonen J, Simonen P, et al
    End-Stage Heart Failure in Cardiac Sarcoidosis.
    Circulation. 2024;149:885-887.
    >> Share

    February 2024
  11. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
    mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
    Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
    >> Share

  12. CRESCI S, Bach RG, Saberi S, Owens AT, et al
    Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Circulation. 2024;149:498-509.
    >> Share

  13. GREEN JB, Everett BM, Ghosh A, Younes N, et al
    Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
    >> Share

  14. JIANG Y, Gu J, Niu X, Hu J, et al
    Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519.
    >> Share

  15. SANCHEZ RH, Hamdan H, Torrealba J, Grodin JL, et al
    Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias.
    Circulation. 2024;149:475-480.
    >> Share

    January 2024
  16. HERWEG B, Sharma PS, Cano O, Ponnusamy SS, et al
    Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.
    Circulation. 2024;149:379-390.
    >> Share

  17. SUMARSONO A, Xie L, Keshvani N, Zhang C, et al
    Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Circulation. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.067489.
    >> Share

  18. BROMAN MT, Nadadur RD, Perez-Cervantes C, Burnicka-Turek O, et al
    A Genomic Link From Heart Failure to Atrial Fibrillation Risk: FOG2 Modulates a TBX5/GATA4-Dependent Atrial Gene Regulatory Network.
    Circulation. 2024 Jan 8. doi: 10.1161/CIRCULATIONAHA.123.066804.
    >> Share

    December 2023
  19. REN Z, Zhao W, Li D, Yu P, et al
    INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440.
    >> Share

  20. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    >> Share

  21. THOMPSON PD
    Steps May Count for More Than Just Cardiac Risk.
    Circulation. 2023;148:2017-2018.
    >> Share

  22. GOSS KN
    Preterm Birth: An Overlooked Risk Factor for Heart Failure in the Young Adult.
    Circulation. 2023;148:2005-2007.
    >> Share

  23. GOLDENBERG JR, Hays AG, Gabr RE, Sch?r M, et al
    Energetic Basis of Recovered Ejection Fraction in Human Heart Failure.
    Circulation. 2023;148:1976-1978.
    >> Share

  24. VAN DUIJVENBODEN S, Ramirez J, Orini M, Aung N, et al
    Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects.
    Circulation. 2023;148:1932-1944.
    >> Share

  25. MCMURRAY JJV, Docherty KF, de Boer RA, Hammarstedt A, et al
    Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    Circulation. 2023 Dec 7. doi: 10.1161/CIRCULATIONAHA.123.065061.
    >> Share

    November 2023
  26. GREENE SJ, Butler J
    Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics.
    Circulation. 2023;148:1746-1749.
    >> Share

  27. WALKER MA, Chen H, Yadav A, Ritterhoff J, et al
    Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation.
    Circulation. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039.
    >> Share

  28. XU W, Billon C, Li H, Wilderman A, et al
    Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
    Circulation. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542.
    >> Share

  29. WHELLAN DJ
    Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588.
    >> Share

  30. VETROVSKY T, Siranec M, Frybova T, Gant I, et al
    Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395.
    >> Share

  31. KOSIBOROD MN, Verma S, Borlaug BA, Butler J, et al
    Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505.
    >> Share

  32. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
    Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
    Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
    >> Share

  33. KHAN SS, Coresh J, Pencina MJ, Ndumele CE, et al
    Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Nov 10. doi: 10.1161/CIR.0000000000001191.
    >> Share

  34. KHAN SS, Matsushita K, Sang Y, Ballew SH, et al
    Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations.
    Circulation. 2023 Nov 10. doi: 10.1161/CIRCULATIONAHA.123.067626.
    >> Share

  35. BAWASKAR P, Thomas N, Ismail KF, Guo Y, et al
    Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease.
    Circulation. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067032.
    >> Share

    October 2023
  36. ZAMANI SK, Sarma S, MacNamara JP, Hynan LS, et al
    Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023;148:1410-1412.
    >> Share

  37. WAKEHAM DJ, Ivey E, Saland S, Lewis J, et al
    Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170.
    >> Share

  38. OSTROMINSKI JW, Vaduganathan M, Selvaraj S, Claggett BL, et al
    Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254.
    >> Share

  39. BUTT JH, Yafasova A, Doi SN, Nielsen JC, et al
    Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial.
    Circulation. 2023;148:1179-1181.
    >> Share

    September 2023
  40. GODFREY S, Kirkpatrick JN, Kramer DB, Sulistio MS, et al
    Expanding the Paradigm for Cardiovascular Palliative Care.
    Circulation. 2023;148:1039-1052.
    >> Share

  41. PARKASH R, O'Meara E, Tang ASL
    The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure.
    Circulation. 2023;148:933-935.
    >> Share

  42. LEBEK S, Caravia XM, Chemello F, Tan W, et al
    Elimination of CaMKIIdelta Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice.
    Circulation. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117.
    >> Share

  43. COCHRAN J, Yura Y, Thel MC, Doviak H, et al
    Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170.
    >> Share

  44. CHEW DS, Li Y, Bigelow R, Cowper PA, et al
    Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.
    >> Share

  45. ZHU H, Song YC, Hang PZ
    Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:855-856.
    >> Share

  46. ARONSEN JM, Skogestad J, Albert I, Melleby AO, et al
    Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:857-858.
    >> Share

    August 2023
  47. HEIDENREICH P
    What Is a Normal Left Ventricular Ejection Fraction?
    Circulation. 2023;148:750-752.
    >> Share

  48. CHATUR S, Vaduganathan M, Claggett BL, Cunningham JW, et al
    Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506.
    >> Share

  49. PACKER M, Butler J, Zeller C, Pocock SJ, et al
    Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Circulation. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748.
    >> Share


  50. Correction to: Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2023;148:e7.
    >> Share

  51. SARMA S, Levine BD
    Response by Sarma and Levine to Letters Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:620-621.
    >> Share

  52. WUSSLER D, Belkin M, Mueller C
    Letter by Wussler et al Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:619.
    >> Share

  53. RAGONE I, Barallobre-Barreiro J, Takov K, Theofilatos K, et al
    SERCA2a Protein Levels Are Unaltered in Human Heart Failure.
    Circulation. 2023;148:613-616.
    >> Share

  54. DIMOPOULOS S, Nanas S
    Letter by Dimopoulos and Nanas Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:617-618.
    >> Share

  55. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    >> Share

    July 2023
  56. PACKER M, Wilcox CS, Testani JM
    Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Circulation. 2023;148:354-372.
    >> Share

  57. MENTIAS A, Mujahid MS, Sumarsono A, Nelson RK, et al
    Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
    Circulation. 2023;148:210-219.
    >> Share

  58. WATSON WD, Green PG, Lewis AJM, Arvidsson P, et al
    Retained Metabolic Flexibility of the Failing Human Heart.
    Circulation. 2023;148:109-123.
    >> Share

  59. GHADIMI K, Cappiello JL, Wright MC, Levy JH, et al
    Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
    Circulation. 2023 Jul 4. doi: 10.1161/CIRCULATIONAHA.122.062464.
    >> Share

    June 2023
  60. KONDO T, Dewan P, Anand IS, Desai AS, et al
    Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
    Circulation. 2023 Jun 27. doi: 10.1161/CIRCULATIONAHA.122.063642.
    >> Share

  61. HITSUMOTO T, Tsukamoto O, Matsuoka K, Li J, et al
    Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.
    Circulation. 2023;147:1902-1918.
    >> Share

    May 2023
  62. TANG Y, Feng M, Su Y, Ma T, et al
    Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
    Circulation. 2023;147:1684-1704.
    >> Share

  63. GREENE SJ, Velazquez EJ, Anstrom KJ, Clare RM, et al
    Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
    Circulation. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842.
    >> Share

  64. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
    Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
    Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
    >> Share

  65. GUPTA K, Spertus JA, Birmingham M, Gosch KL, et al
    Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
    Circulation. 2023 May 16. doi: 10.1161/CIRCULATIONAHA.122.063263.
    >> Share

  66. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    >> Share

    April 2023
  67. HUNDERTMARK MJ, Adler A, Antoniades C, Coleman R, et al
    Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
    Circulation. 2023 Apr 18. doi: 10.1161/CIRCULATIONAHA.122.062021.
    >> Share

  68. BUTLER J, Talha KM, Fonarow GC
    STRONG-HF and Implementing Heart Failure Therapies: Godspeed ... With Care.
    Circulation. 2023;147:1189-1191.
    >> Share

  69. FILIPPATOS G, Ponikowski P, Farmakis D, Anker SD, et al
    Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Circulation. 2023 Apr 13. doi: 10.1161/CIRCULATIONAHA.122.060757.
    >> Share

  70. ERN YEOH S, Docherty KF, Campbell RT, Jhund PS, et al
    Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2023 Apr 11. doi: 10.1161/CIRCULATIONAHA.122.063327.
    >> Share

  71. MENTIAS A, Peterson ED, Keshvani N, Kumbhani DJ, et al
    Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
    Circulation. 2023;147:1121-1133.
    >> Share


  72. Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;147:e674.
    >> Share

  73. BUTT JH, Solomon SD, McMurray JJV
    Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1119-1120.
    >> Share

  74. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    >> Share

    March 2023
  75. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
    Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Circulation. 2023 Mar 21. doi: 10.1161/CIR.0000000000001122.
    >> Share

  76. SELVARAJ S, Kosiborod MN, Shah SH
    Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:922-923.
    >> Share

  77. TACHIBANA S, Yu NK, Li R, Fernandez-Costa C, et al
    Perm1 Protects the Heart From Pressure Overload-Induced Dysfunction by Promoting Oxidative Metabolism.
    Circulation. 2023;147:916-919.
    >> Share

  78. MONZO L, Melenovsky V
    Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:920-921.
    >> Share

  79. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    >> Share

  80. KUEHN BM
    Collaborative Care Model Helps Patients With Heart Failure Meet End-of-Life Goals.
    Circulation. 2023;147:841-842.
    >> Share

  81. FRIEDMAN DJ, Al-Khatib SM, Dalgaard F, Fudim M, et al
    Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.
    Circulation. 2023;147:812-823.
    >> Share

  82. SKOGESTAD J, Albert I, Hougen K, Lothe GB, et al
    Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.121.054168.
    >> Share

  83. KONDO T, Jering KS, Borleffs CJW, de Boer RA, et al
    Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.122.062918.
    >> Share

  84. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    >> Share

    February 2023
  85. LEYVA F, Israel CW, Singh J
    Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Circulation. 2023;147:759-767.
    >> Share

  86. FELKER GM, North R, Mulder H, Jones WS, et al
    Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study.
    Circulation. 2023;147:694-696.
    >> Share

  87. PINA IL
    Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors.
    Circulation. 2023;147:635-637.
    >> Share

  88. LIAO B
    Letter by Liao Regarding Article, "Association Between Device-Measured Physical Activity and Incident Heart Failure: A Prospective Cohort Study of 94 739 UK Biobank Participants".
    Circulation. 2023;147:e92.
    >> Share

  89. SAWAMI K, Tanaka A, Node K
    Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e73-e74.
    >> Share

  90. CAPONE F, Vettor R, Schiattarella GG
    Cardiometabolic HFpEF: NASH of the Heart.
    Circulation. 2023;147:451-453.
    >> Share

  91. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
    Response by Schulze et al to Letter Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e75.
    >> Share

    January 2023
  92. BERRY JD, Chen H, Nambi V, Ambrosius WT, et al
    Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT.
    Circulation. 2023;147:310-323.
    >> Share

  93. NTSEKHE M, Baker JV
    Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context.
    Circulation. 2023;147:83-100.
    >> Share

    December 2022
  94. PALUCH AE, Bajpai S, Ballin M, Bassett DR, et al
    Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
    Circulation. 2022 Dec 20. doi: 10.1161/CIRCULATIONAHA.122.061288.
    >> Share

  95. BERGH N, Skoglund K, Fedchenko M, Bollano E, et al
    Risk of Heart Failure in Congenital Heart Disease: A Nationwide Register-based Cohort Study.
    Circulation. 2022 Dec 19. doi: 10.1161/CIRCULATIONAHA.122.061546.
    >> Share

  96. SARMA S, MacNamara JP, Balmain BN, Hearo CM Jr, et al
    Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061828.
    >> Share

  97. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
    Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
    >> Share

  98. MARX N, Husain M, Lehrke M, Verma S, et al
    GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Circulation. 2022;146:1882-1894.
    >> Share

  99. ALAHMAD B, Khraishah H, Roye D, Vicedo-Cabrera AM, et al
    Associations Between Extreme Temperatures and Cardiovascular Cause-Specific Mortality: Results From 27 Countries.
    Circulation. 2022 Dec 12. doi: 10.1161/CIRCULATIONAHA.122.061832.
    >> Share

  100. TANI H, Sadahiro T, Yamada Y, Isomi M, et al
    Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.
    Circulation. 2022 Dec 12. doi: 10.1161/CIRCULATIONAHA.121.058655.
    >> Share

  101. CHOW SL, Bozkurt B, Baker WL, Bleske BE, et al
    Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Dec 8. doi: 10.1161/CIR.0000000000001110.
    >> Share

    November 2022
  102. DRAKOS SG, Badolia R, Makaju A, Kyriakopoulos CP, et al
    Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support.
    Circulation. 2022 Nov 30. doi: 10.1161/CIRCULATIONAHA.121.056600.
    >> Share

  103. WEIR RAP
    The EMPEROR's New Clothes: Aren't We Just Treating Grades of Heart Failure With Reduced Ejection Fraction?
    Circulation. 2022;146:1489-1491.
    >> Share

  104. SHETTY NS, Parcha V, Hasnie A, Pandey A, et al
    Mechanical Circulatory Support Devices Among Patients With Familial Dilated Cardiomyopathy: Insights From the INTERMACS.
    Circulation. 2022;146:1486-1488.
    >> Share

  105. VERMA S, Dhingra NK, Butler J, Anker SD, et al
    Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062644.
    >> Share

  106. WANG X, Vaduganathan M, Claggett BL, Hegde SM, et al
    Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.
    >> Share

  107. MARTENS P, Dauw J, Verbrugge FH, Nijst P, et al
    Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062486.
    >> Share

  108. CONNELLY KA, Mazer CD, Puar P, Teoh H, et al
    Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062769.
    >> Share

  109. MEHRAN R, Steg PG, Pfeffer MA, Jering K, et al
    The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Circulation. 2022 Nov 2. doi: 10.1161/CIRCULATIONAHA.122.060841.
    >> Share

  110. KASS DA
    What's EF Got to Do, Got to Do With It?
    Circulation. 2022;146:1327-1328.
    >> Share

    October 2022
  111. ERCU M, Mucke MB, Pallien T, Marko L, et al
    Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage.
    Circulation. 2022 Oct 19:101161CIRCULATIONAHA122060210.
    >> Share

  112. JANUZZI JL, Omar AMS, Liu Y, Murphy S, et al
    Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Circulation. 2022 Oct 2. doi: 10.1161/CIRCULATIONAHA.122.061693.
    >> Share

    September 2022

  113. Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022;146:e185.
    >> Share


  114. Correction to: Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation.
    Circulation. 2022;146:e186.
    >> Share

  115. BUTLER J, Filippatos G, Jamal Siddiqi T, Pedro Ferreira J, et al
    Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Circulation. 2022 Sep 13:101161CIRCULATIONAHA122059755.
    >> Share


  116. Correction to: Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
    Circulation. 2022;146:e167.
    >> Share

  117. SANTOS-GALLEGO CG, Mayr M, Badimon J
    SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism.
    Circulation. 2022;146:819-821.
    >> Share

  118. SHAH AM, Claggett B, Prasad N, Li G, et al
    Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Circulation. 2022 Sep 9:101161CIRCULATIONAHA122059210.
    >> Share

    August 2022
  119. ZHAO Y, Riching AS, Knight WE, Chi C, et al
    Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart.
    Circulation. 2022;146:699-714.
    >> Share

  120. HO FK, Zhou Z, Petermann-Rocha F, Para-Soto S, et al
    Association Between Device-Measured Physical Activity and Incident Heart Failure: A Prospective Cohort Study of 94 739 UK Biobank Participants.
    Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.059663.
    >> Share

  121. LAM CSP, Solomon SD
    DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.062022.
    >> Share

  122. BUTT JH, Jhund PS, Belohlavek J, de Boer RA, et al
    Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.061754.
    >> Share

  123. ZHANG L, Cunningham JW, Claggett BL, Jacob J, et al
    Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.061481.
    >> Share

  124. WEDIN JO, Vedin O, Rodin S, Simonson OE, et al
    Patients With Bicuspid Aortic Stenosis Demonstrate Adverse Left Ventricular Remodeling and Impaired Cardiac Function Before Surgery With Increased Risk of Postoperative Heart Failure.
    Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060125.
    >> Share

  125. DOCHERTY KF, Welsh P, Verma S, De Boer RA, et al
    Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060511.
    >> Share

  126. BRENER MI, Borlaug BA, Burkhoff D
    HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues.
    Circulation. 2022;146:519-522.
    >> Share

  127. SORIMACHI H, Verbrugge FH, Omote K, Omar M, et al
    Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels.
    Circulation. 2022;146:500-502.
    >> Share

  128. GELLER BJ, Sinha SS, Kapur NK, Bakitas M, et al
    Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association.
    Circulation. 2022;146:e50-e68.
    >> Share

    July 2022

  129. Correction to: Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
    Circulation. 2022;146:e12.
    >> Share

  130. ANKER SD, Usman MS, Butler J
    SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Circulation. 2022;146:299-302.
    >> Share

  131. REDDY YNV, Borlaug BA, Gersh BJ
    Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction.
    Circulation. 2022;146:339-357.
    >> Share

  132. PANDEY A, Keshvani N, Wang TJ
    Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction?
    Circulation. 2022;146:276-278.
    >> Share

  133. LEE MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, et al
    Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2022;146:364-367.
    >> Share

  134. PETERSON LR, Coggan AR
    Heart Failure With Reduced Ejection Fraction: "The Importance of Being Frail".
    Circulation. 2022;146:91-93.
    >> Share

  135. BRITTAIN EL, Thenappan T, Huston JH, Agrawal V, et al
    Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.
    Circulation. 2022 Jul 11:101161CIR0000000000001079.
    >> Share

  136. ROSCH S, Kresoja KP, Besler C, Fengler K, et al
    Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction.
    Circulation. 2022 Jul 8:101161CIRCULATIONAHA122059280.
    >> Share

  137. TONG D, Schiattarella GG, Jiang N, Daou D, et al
    Impaired AMP-Activated Protein Kinase Signaling in Heart Failure With Preserved Ejection Fraction-Associated Atrial Fibrillation.
    Circulation. 2022;146:73-76.
    >> Share

    June 2022
  138. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
    Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Circulation. 2022 Jun 29:101161CIRCULATIONAHA122059038.
    >> Share

  139. FILIPPATOS G, Butler J, Farmakis D, Zannad F, et al
    Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Circulation. 2022 Jun 28:101161CIRCULATIONAHA122059785.
    >> Share

  140. ABDEL-QADIR H, Akioyamen LE, Fang J, Pang A, et al
    Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study.
    Circulation. 2022 Jun 9:101161CIRCULATIONAHA122058949.
    >> Share

  141. POKORNEY SD, Granger CB
    Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure.
    Circulation. 2022;145:1705-1707.
    >> Share

    May 2022
  142. PANDEY A, Segar MW, Singh S, Reeves G, et al
    Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.
    Circulation. 2022 May 26:101161CIRCULATIONAHA122059983.
    >> Share

  143. GIBB AA, Murray EK, Huynh AT, Gaspar RB, et al
    Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure.
    Circulation. 2022;145:1625-1628.
    >> Share

  144. SAUNDERS A, Michelakis E
    Atrial Shunt Devices in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction and the Pulmonary Circulation: Promises and Concerns.
    Circulation. 2022;145:1605-1608.
    >> Share

  145. VADUGANATHAN M, Claggett BL, Inciardi RM, Fonarow GC, et al
    Estimating the Benefits of Combination Medical Therapy in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.121.058929.
    >> Share

  146. SELVARAJ S, Fu Z, Jones P, Kwee LC, et al
    Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.
    >> Share

  147. VADUGANATHAN M, Claggett BL, McMurray JJV, Solomon SD, et al
    Health Status Trajectories Before and After Hospitalization for Heart Failure.
    Circulation. 2022 May 21. doi: 10.1161/CIRCULATIONAHA.122.059282.
    >> Share

  148. FURTADO RHM, Raz I, Goodrich EL, Murphy SA, et al
    Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
    Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.
    >> Share


  149. Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022;145:e1033.
    >> Share

  150. PAULUS WJ
    Border Disputes Between Heart Failure Phenotypes.
    Circulation. 2022;145:1374-1376.
    >> Share

    April 2022
  151. ADAMSON C, Docherty KF, Heerspink HJL, de Boer RA, et al
    Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
    Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.
    >> Share

  152. GRONDA E, Colivicchi F, Zuccala G
    Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial".
    Circulation. 2022;145:e839-e840.
    >> Share

  153. MAKAREWICH CA, Thum T
    Exercise-Induced Long Noncoding RNAs As New Players in Cardiac Hypertrophy.
    Circulation. 2022;145:1234-1237.
    >> Share

  154. LI H, Trager LE, Liu X, Hastings MH, et al
    lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth.
    Circulation. 2022;145:1218-1233.
    >> Share

  155. REED AK, Chiu P, Carreon CK, Sanders SP, et al
    Unrepairable Infant Mitral Valve: An Unexpected Case of Decompensated Heart Failure.
    Circulation. 2022;145:1175-1178.
    >> Share

  156. HARRINGTON J, Mentz RJ
    Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction.
    Circulation. 2022;145:1105-1107.
    >> Share

  157. ZHANG J, Liang R, Wang K, Zhang W, et al
    Novel CaMKII-delta Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth.
    Circulation. 2022;145:1154-1168.
    >> Share

  158. CAO Y, Pan C, Wang YC, Zhou Z, et al
    Identification of DNA Damage Repair Enzyme Ascc2 as Causal for Heart Failure With Preserved Ejection Fraction.
    Circulation. 2022;145:1102-1104.
    >> Share

  159. KOSIBOROD MN, Angermann CE, Collins SP, Teerlink JR, et al
    Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure - Results From the EMPULSE Trial.
    Circulation. 2022 Apr 4. doi: 10.1161/CIRCULATIONAHA.122.059725.
    >> Share

  160. DELLA BELLA P, Baratto F, Vergara P, Bertocchi P, et al
    Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.
    Circulation. 2022 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.059598.
    >> Share

  161. MORRIS AA, Butler J
    The Updated Heart Failure Guidelines: Time for a Refresh.
    Circulation. 2022 Apr 1. doi: 10.1161/CIRCULATIONAHA.122.059104.
    >> Share

  162. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022 Apr 1:101161CIR0000000000001062.
    >> Share

  163. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022 Apr 1:101161CIR0000000000001063.
    >> Share

    March 2022
  164. BORLAUG BA, Blair J, Bergmann MW, Bugger H, et al
    Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
    Circulation. 2022 Mar 31. doi: 10.1161/CIRCULATIONAHA.122.059486.
    >> Share

  165. HEGYI B, Mira Hernandez J, Shen EY, Habibi NR, et al
    Empagliflozin Reverses Late Na(+) Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2022;145:1029-1031.
    >> Share

  166. PARKASH R, Wells GA, Rouleau J, Talajic M, et al
    Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
    Circulation. 2022 Mar 22. doi: 10.1161/CIRCULATIONAHA.121.057095.
    >> Share

  167. HENRY A, Gordillo-Maranon M, Finan C, Schmidt AF, et al
    Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.
    Circulation. 2022 Mar 18. doi: 10.1161/CIRCULATIONAHA.121.056663.
    >> Share

  168. WOLLERT KC
    Response by Wollert to Letter Regarding Article, "Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure".
    Circulation. 2022;145:e770.
    >> Share

  169. FENG J, Nie Y
    Letter by Feng and Nie Regarding Article, "Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure".
    Circulation. 2022;145:e768-e769.
    >> Share

  170. FENG G, Bajpai G, Ma P, Koenig A, et al
    CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells.
    Circulation. 2022;145:765-782.
    >> Share

  171. ZHUANG L, Jia K, Chen C, Li Z, et al
    DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics.
    Circulation. 2022 Mar 2. doi: 10.1161/CIRCULATIONAHA.121.055727.
    >> Share

  172. BELDHUIS IE, Lam CSP, Testani JM, Voors AA, et al
    Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
    Circulation. 2022;145:693-712.
    >> Share

  173. HIEDA M, Levine BD
    Response by Hieda and Levine to Letter Regarding Article, "One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2022;145:e644.
    >> Share

  174. HUANG LUCAS C, Taegtmeyer H
    Letter by Lucas and Taegtmeyer Regarding Article, "One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2022;145:e642-e643.
    >> Share

    February 2022

  175. Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Circulation. 2022;145:e641.
    >> Share

  176. TALEB I, Tseliou E, Fang JC, Drakos SG, et al
    A Mechanical Bridge to Recovery as a Bridge to Discovery: Learning From Few and Applying to Many.
    Circulation. 2022;145:562-564.
    >> Share

    January 2022
  177. ABOULEISA RRE, Salama ABM, Ou Q, Tang XL, et al
    Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure.
    Circulation. 2022 Jan 21. doi: 10.1161/CIRCULATIONAHA.121.057641.
    >> Share

    December 2021
  178. MESQUITA T, Zhang R, Cho JH, Zhang R, et al
    Mechanisms of Sinoatrial Node Dysfunction in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2021 Dec 14. doi: 10.1161/CIRCULATIONAHA.121.054976.
    >> Share

  179. MODICA J, Di Mauro V, Barandalla-Sobrados M, Chavez SEP, et al
    Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure.
    Circulation. 2021;144:1973-1976.
    >> Share

  180. YAFASOVA A, Butt JH, Elming MB, Nielsen JC, et al
    Long-term Follow-up of the The Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH).
    Circulation. 2021 Dec 9. doi: 10.1161/CIRCULATIONAHA.121.056072.
    >> Share

  181. PATEL KV, Segar MW, Lavie CJ, Kondamudi N, et al
    Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts.
    Circulation. 2021 Dec 3. doi: 10.1161/CIRCULATIONAHA.121.055830.
    >> Share

    November 2021
  182. ABDELLATIF M, Sedej S, Kroemer G
    NAD(+) Metabolism in Cardiac Health, Aging, and Disease.
    Circulation. 2021;144:1795-1817.
    >> Share

  183. BARALLOBRE-BARREIRO J, Radovits T, Fava M, Mayr U, et al
    The Extracellular Matrix in Heart Failure: The Role of Adamts5 In Proteoglycan Remodelling.
    Circulation. 2021 Nov 22. doi: 10.1161/CIRCULATIONAHA.121.055732.
    >> Share

  184. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
    Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.
    >> Share

  185. BUTLER J, Filippatos G, Siddiqi TJ, Brueckmann M, et al
    Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Circulation. 2021 Nov 15. doi: 10.1161/CIRCULATIONAHA.121.057812.
    >> Share

  186. FILIPPATOS G, Anker SD, Agarwal R, Ruilope LM, et al
    Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.
    Circulation. 2021 Nov 13. doi: 10.1161/CIRCULATIONAHA.121.057983.
    >> Share

  187. BURRAGE MK, Hundertmark M, Valkovic L, Watson WD, et al
    Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.054858.
    >> Share

  188. MENTIAS A, Desai MY, Vaughan-Sarrazin MS, Rao S, et al
    Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries.
    Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057756.
    >> Share

  189. BERG DD, Docherty KF, Sattar N, Jarolim P, et al
    Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
    Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852.
    >> Share

  190. HO JE, Nguyen C, Lewis GD
    Unmasking Nonpreserved Heart Structure, Function, and Energetics in Heart Failure With Preserved Ejection Fraction With Magnetic Resonance Imaging Coupled With Exercise.
    Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.056974.
    >> Share

    October 2021
  191. YAZAKI Y, Nakamura M, Iijima R, Yasuda S, et al
    Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
    Circulation. 2021;144:1449-1451.
    >> Share

  192. HAN YS, Arteaga GM, Sharain K, Sieck GC, et al
    Rat Model of Heart Failure With Preserved Ejection Fraction: Changes in Contractile Proteins Regulating Ca(2+) Cycling and Vascular Reactivity.
    Circulation. 2021;144:1355-1358.
    >> Share

  193. MEYER M, LeWinter MM, Zile MR
    A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone.
    Circulation. 2021;144:1269-1271.
    >> Share

  194. HAJJAR RJ, Leopold JA
    Inflammation and Heart Failure: Friend or Foe?
    Circulation. 2021;144:1241-1243.
    >> Share

    September 2021

  195. Correction to: Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;144:e212.
    >> Share

  196. HIEDA M, Sarma S, Hearon CM Jr, MacNamara JP, et al
    One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.
    Circulation. 2021;144:934-946.
    >> Share

  197. MORRIS AA, Khazanie P, Drazner MH, Albert NM, et al
    Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2021 Sep 10:CIR0000000000001016. doi: 10.1161/CIR.0000000000001016.
    >> Share

  198. DANIELS MJ, Fusi L, Semsarian C, Naidu SS, et al
    Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine.
    Circulation. 2021;144:759-762.
    >> Share

    August 2021
  199. ZHAO D, Zhong G, Li J, Pan J, et al
    Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
    Circulation. 2021;144:694-711.
    >> Share

  200. LI Q, Li C, Elnwasany A, Sharma G, et al
    PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart.
    Circulation. 2021;144:712-727.
    >> Share

  201. PACKER M, Butler J, Zannad F, Filippatos G, et al
    Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056824.
    >> Share

  202. PACKER M, Zannad F, Anker SD
    Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials.
    Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056657.
    >> Share

  203. EZEKOWITZ JA, Zheng Y, Cohen-Solal A, Melenovsky V, et al
    Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
    Circulation. 2021 Aug 25. doi: 10.1161/CIRCULATIONAHA.121.056797.
    >> Share

  204. ANKER SD, Ponikowski P, Wanner C, Pfarr E, et al
    Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Circulation. 2021 Aug 16. doi: 10.1161/CIRCULATIONAHA.121.054669.
    >> Share

  205. KORF-KLINGEBIEL M, Reboll MR, Polten F, Weber N, et al
    Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca(2+)-ATPase Expression in Cardiomyocytes.
    Circulation. 2021 Aug 10. doi: 10.1161/CIRCULATIONAHA.120.053365.
    >> Share

    July 2021
  206. RILLIG A, Magnussen C, Ozga AK, Suling A, et al
    Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure.
    Circulation. 2021 Jul 30. doi: 10.1161/CIRCULATIONAHA.121.056323.
    >> Share

  207. SAWICKI KT, Ardehali H
    Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency.
    Circulation. 2021;144:253-255.
    >> Share

  208. LEE MMY, McMurray JJV, Jhund PS, Petrie MC, et al
    Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
    Circulation. 2021;144:e40.
    >> Share

  209. SINGH JS, Struthers AD, Lang CC
    Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
    Circulation. 2021;144:e38-e39.
    >> Share

  210. FELKER GM, Butler J, Ibrahim NE, Pina IL, et al
    Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
    Circulation. 2021;144:180-182.
    >> Share

  211. KALYANASUNDARAM A, Li N, Gardner ML, Artiga EJ, et al
    Fibroblast-Specific Proteotranscriptomes Reveal Distinct Fibrotic Signatures of Human Sinoatrial Node in Nonfailing and Failing Hearts.
    Circulation. 2021;144:126-143.
    >> Share

    June 2021
  212. SATOH T, Wang L, Espinosa-Diez C, Wang B, et al
    Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Down Regulation of sGC and Contributes to Exercise-Induced Pulmonary Hypertension in HFpEF.
    Circulation. 2021 Jun 23. doi: 10.1161/CIRCULATIONAHA.121.053889.
    >> Share

  213. ANAND V, Bradley D, Frye RL, Borlaug BA, et al
    Things Are Not Always as They Seem: Multimodality Exercise Assessment in the Evaluation of Dyspnea.
    Circulation. 2021;143:2502-2507.
    >> Share

  214. BREATHETT K, Knapp SM, Carnes M, Calhoun E, et al
    Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients.
    Circulation. 2021;143:2412-2414.
    >> Share

  215. MORRIS AA, Testani JM, Butler J
    Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities.
    Circulation. 2021;143:2329-2331.
    >> Share


  216. Correction to: Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2021;143:e1027.
    >> Share

  217. FELKER GM, Butler J, Januzzi JL Jr, Desai AS, et al
    Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
    Circulation. 2021;143:2316-2318.
    >> Share

  218. BIRKS EJ, Rame JE, Cunningham C, Drakos SG, et al
    Response by Birks et al to Letters Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1017-e1018.
    >> Share

  219. JENSEN J, Omar M, Kistorp C, Tuxen C, et al
    Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
    Circulation. 2021;143:2208-2210.
    >> Share

  220. MEHMOOD M
    Letter by Mehmood Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1014.
    >> Share

  221. MOAYEDI Y, Runeckles K, Posada JD
    Letter by Moayedi et al Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
    Circulation. 2021;143:e1015-e1016.
    >> Share

    May 2021
  222. KAR S, Mack MJ, Lindenfeld J, Abraham WT, et al
    Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: The COAPT Trial.
    Circulation. 2021 May 27. doi: 10.1161/CIRCULATIONAHA.120.053061.
    >> Share

  223. LOPES RD, Alexander KP, Hochman JS, Maron DJ, et al
    Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
    Circulation. 2021;143:e961-e962.
    >> Share

  224. MORGAN H, Clayton T, Perera D
    Letter by Morgan et al Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
    Circulation. 2021;143:e959-e960.
    >> Share

  225. CARLEY AN, Maurya SK, Fasano M, Wang Y, et al
    Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart.
    Circulation. 2021;143:1797-1808.
    >> Share

    April 2021
  226. JOHANSSON I, Joseph P, Balasubramanian K, McMurray JJV, et al
    Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23,000 Patients from 40 Countries.
    Circulation. 2021 Apr 28. doi: 10.1161/CIRCULATIONAHA.120.050850.
    >> Share


  227. Correction to: Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death.
    Circulation. 2021;143:e892.
    >> Share

  228. KANEKO H, Yano Y, Itoh H, Morita K, et al
    Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Risk of Heart Failure and Atrial Fibrillation.
    Circulation. 2021 Apr 22. doi: 10.1161/CIRCULATIONAHA.120.052624.
    >> Share

  229. SEGAR MW, Jaeger BC, Patel KV, Nambi V, et al
    Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multi-Cohort Analysis.
    Circulation. 2021 Apr 13. doi: 10.1161/CIRCULATIONAHA.120.053134.
    >> Share

  230. BORLAUG BA, Nelson MD
    Real-Time Cardiac Magnetic Resonance Imaging: A New Spin on the Evaluation of HFpEF.
    Circulation. 2021;143:1499-1501.
    >> Share

  231. RAMANUJAM D, Schon AP, Beck C, Vaccarello P, et al
    MicroRNA-21-Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload.
    Circulation. 2021;143:1513-1525.
    >> Share

  232. JHUND PS, Ponikowski P, Docherty KF, Gasparyan SB, et al
    Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF.
    Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.
    >> Share

  233. ROSENFELD LE, Enriquez AD
    The Cabana Trial and Heart Failure: Some Sun and Some Shade.
    Circulation. 2021;143:1391-1393.
    >> Share

    March 2021
  234. LOOMBA RS, Villarreal EG, Flores S
    Letter by Loomba et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e755-e756.
    >> Share

  235. NAVARRO CASTELLANOS I, Dahdah N
    Letter by Navarro Castellanos and Dahdah Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e759-e760.
    >> Share

  236. CARDENAS SURI H, Jimomila Bening D
    Letter by Cardenas Suri and Jimomila Bening Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e757-e758.
    >> Share

  237. REN C, Qian M, Han C
    Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e761-e762.
    >> Share

  238. YU H, Zhang F, Yan P, Zhang S, et al
    LARP7 Protects Against Heart Failure by Enhancing Mitochondrial Biogenesis.
    Circulation. 2021 Mar 5. doi: 10.1161/CIRCULATIONAHA.120.050812.
    >> Share

  239. PATEL RB, Ter Maaten JM, Ferreira JP, McCausland FR, et al
    Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
    Circulation. 2021;143:949-958.
    >> Share

  240. ASLAM MI, Hahn VS, Jani V, Hsu S, et al
    Reduced Right Ventricular Sarcomere Contractility in Heart Failure With Preserved Ejection Fraction and Severe Obesity.
    Circulation. 2021;143:965-967.
    >> Share

    February 2021
  241. ARAS D, Ozeke O, Topaloglu S
    When You Hear Hoofbeats, Look for Horses, Not Zebras.
    Circulation. 2021;143:862-864.
    >> Share

  242. FORTE E, Perkins B, Sintou A, Kalkat HS, et al
    Cross-Priming Dendritic Cells Exacerbate Immunopathology After Ischemic Tissue Damage in the Heart.
    Circulation. 2021;143:821-836.
    >> Share

  243. YAMAGUCHI N, Xiao J, Narke D, Shaheen D, et al
    Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling.
    Circulation. 2021;143:805-820.
    >> Share

  244. UMAPATHI P, Banerjee PS, Zachara NE, Abrol N, et al
    Excessive O - GlcNAcylation Causes Heart Failure and Sudden Death.
    Circulation. 2021 Feb 17. doi: 10.1161/CIRCULATIONAHA.120.051911.
    >> Share

  245. COOPER LB, Cotugno A, deFilippi C
    Efficacy of Neprilysin Inhibition in Women With HFpEF: Beyond Phenotypes and Natriuretic Peptides.
    Circulation. 2021;143:618-620.
    >> Share

  246. WANG Y, Ma X
    Healthy Coronary Endothelial Cells, Happy Cardiomyocytes.
    Circulation. 2021;143:581-582.
    >> Share

  247. PACKER DL, Piccini JP, Monahan KH, Al-Khalidi HR, et al
    Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.050991.
    >> Share

  248. NASSIF ME, Qintar M, Windsor SL, Jermyn R, et al
    Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.052503.
    >> Share

    January 2021

  249. Correction to: Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced.
    Circulation. 2021;143:e29.
    >> Share


  250. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2021;143:e30.
    >> Share

  251. KOSIBOROD M
    Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Circulation. 2021;143:350-353.
    >> Share

  252. CARNICELLI AP, Mentz RJ
    Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
    Circulation. 2021;143:322-325.
    >> Share

  253. HANG PZ, Zhao J
    Letter by Hang and Zhao Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e24-e25.
    >> Share

  254. VANDECASTEELE G, Mika D, Margaria JP, Ghigo A, et al
    Response by Vandecasteele et al to Letter Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e26-e27.
    >> Share

  255. BACKHAUS SJ, Lange T, George EF, Hellenkamp K, et al
    Exercise-Stress Real-time Cardiac Magnetic Resonance Imaging for Non-Invasive Characterisation of Heart Failure with Preserved Ejection Fraction: The HFpEF Stress Trial.
    Circulation. 2021 Jan 21. doi: 10.1161/CIRCULATIONAHA.120.051542.
    >> Share

  256. CHURCHILL TW, Li SX, Curreri L, Zern EK, et al
    Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort.
    Circulation. 2021;143:289-291.
    >> Share

  257. PINCKARD KM, Shettigar VK, Wright KR, Abay E, et al
    A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function.
    Circulation. 2021;143:145-159.
    >> Share

    December 2020
  258. MCMURRAY JJV, Packer M
    How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine.
    Circulation. 2020 Dec 30. doi: 10.1161/CIRCULATIONAHA.120.052926.
    >> Share

  259. DAVE CV, Kim SC, Goldfine AB, Glynn RJ, et al
    Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
    Circulation. 2020 Dec 11. doi: 10.1161/CIRCULATIONAHA.120.047965.
    >> Share

  260. ZANNAD F, Cowie MR
    VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.
    Circulation. 2020;142:2216-2218.
    >> Share

    November 2020
  261. EZEKOWITZ JA, Savu A, Welsh RC, McAlister FA, et al
    Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?
    Circulation. 2020 Nov 30. doi: 10.1161/CIRCULATIONAHA.120.048015.
    >> Share

  262. SARMA S, Howden E, Lawley J, Samels M, et al
    Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Nov 18. doi: 10.1161/CIRCULATIONAHA.120.048338.
    >> Share

  263. ALLEN LA, Venechuk G, McIlvennan CK, Page Ii RL, et al
    An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial.
    Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.051863.
    >> Share


  264. Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Circulation. 2020;142:e369.
    >> Share

  265. LI X, Xue Q, Wang M, Zhou T, et al
    Adherence to a Healthy Sleep Pattern and Incident Heart Failure: A Prospective Study of 408802 UK Biobank Participants.
    Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.050792.
    >> Share

  266. LEE MMY, Brooksbank KJM, Wetherall K, Mangion K, et al
    Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.052186.
    >> Share

  267. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.
    Circulation. 2020 Nov 11. doi: 10.1161/CIRCULATIONAHA.120.051824.
    >> Share

  268. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
    Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e319-e320.
    >> Share

  269. LAU CP, Tse HF
    Letter by Lau and Tse Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e317-e318.
    >> Share

  270. ALBERT CL, Carmona-Rubio AE, Weiss AJ, Procop GG, et al
    The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2.
    Circulation. 2020;142:1865-1870.
    >> Share

  271. PATEL KV, Bahnson JL, Gaussoin SA, Johnson KC, et al
    Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
    Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050941.
    >> Share


  272. Correction to: Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020;142:e316.
    >> Share

  273. HO JE, Redfield MM, Lewis GD, Paulus WJ, et al
    Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2020;142:1770-1780.
    >> Share

    October 2020
  274. HAHN VS, Knutsdottir H, Luo X, Bedi K, et al
    Myocardial Gene Expression Signatures in Human Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Oct 29. doi: 10.1161/CIRCULATIONAHA.120.050498.
    >> Share

  275. BIRKS EJ, Drakos SG, Patel SR, Lowes BD, et al
    A Prospective Multicentre Study of Myocardial Recovery Using Left Ventricular Assist Devices (REmission from Stage D Heart Failure: RESTAGE-HF): Medium Term and Primary Endpoint Results.
    Circulation. 2020 Oct 26. doi: 10.1161/CIRCULATIONAHA.120.046415.
    >> Share

  276. ZANNAD F, Ferreira JP, Pocock SJ, Zeller C, et al
    Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 23. doi: 10.1161/CIRCULATIONAHA.120.051685.
    >> Share

  277. PACKER M, Anker SD, Butler J, Filippatos GS, et al
    Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 21. doi: 10.1161/CIRCULATIONAHA.120.051783.
    >> Share

  278. THIBODEAU JT, Gorodeski EZ
    Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure.
    Circulation. 2020;142:1507-1509.
    >> Share


  279. Correction to: Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Circulation. 2020;142:e234.
    >> Share


  280. Correction to: Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020;142:e236.
    >> Share

  281. JHUND PS, Solomon SD, Docherty KF, Heerspink HJL, et al
    Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF.
    Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.
    >> Share

  282. SANDERS-VAN WIJK S, Tromp J, Beussink-Nelson L, Hage C, et al
    Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study.
    Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.045810.
    >> Share

  283. COSENTINO F, Cannon CP, Cherney DZI, Masiukiewicz U, et al
    Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Circulation. 2020 Oct 7. doi: 10.1161/CIRCULATIONAHA.120.050255.
    >> Share

    September 2020
  284. TOBE SW, Poon S
    Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.
    Circulation. 2020;142:1246-1248.
    >> Share

    August 2020
  285. CHEN F, Chen ZQ, Zhu JJ
    Letter by Chen et al Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e67-e68.
    >> Share

  286. LEWIS AA, de Lemos JA
    Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e69-e70.
    >> Share

  287. SIMPSON JM, Newburger JW
    Multisystem Inflammatory Syndrome in Children in Association With COVID-19.
    Circulation. 2020;142:437-440.
    >> Share

    July 2020
  288. OMURA J, Habbout K, Shimauchi T, Wu WH, et al
    Identification of The Long Non-Coding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
    Circulation. 2020 Jul 23. doi: 10.1161/CIRCULATIONAHA.120.047626.
    >> Share

    June 2020
  289. MOAZZAMI K, Wittbrodt MT, Lima BB, Nye JA, et al
    Higher Activation of the Rostromedial Prefrontal Cortex during Mental Stress Predicts Major Cardiovascular Disease Events in Individuals with Coronary Artery Disease.
    Circulation. 2020 Jun 11. doi: 10.1161/CIRCULATIONAHA.119.044442.
    >> Share

  290. LEE H, Yano Y, Cho SMJ, Park JH, et al
    Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults.
    Circulation. 2020;141:1778-1786.
    >> Share

    April 2020
  291. ARMSTRONG PW
    Enhancing Cardiovascular Care: Global Collaboration Is How It Happens.
    Circulation. 2020;141:1357-1359.
    >> Share

    March 2020
  292. CHARTON M, Flecher E, Leclercq C, Delmas C, et al
    Suicide Attempts Among LVAD Recipients: Real-Life Data From the ASSIST-ICD Study.
    Circulation. 2020;141:934-936.
    >> Share

  293. CAPORIZZO MA, Chen CY, Bedi K, Margulies KB, et al
    Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium.
    Circulation. 2020;141:902-915.
    >> Share

  294. SCHIATTARELLA GG, Tong D, Hill JA
    Can HFpEF and HFrEF Coexist?
    Circulation. 2020;141:709-711.
    >> Share

    February 2020
  295. OMIYA S, Omori Y, Taneike M, Murakawa T, et al
    Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.
    Circulation. 2020;141:667-677.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016